Primary systemic amyloidosis
MONDO:0017816Primary systemic amyloidosis (PSA) is a form of AL amyloidosis caused by the aggregation and deposition of insoluble amyloid fibrils derived from misfolded monoclonal immunoglobulin light chains usually produced by a plasma cell tumor and characterized by multiple organ involvement.
Also known as: systemic AL amyloidosis, systemic Immunoglobulin Light chain amyloidosis, systemic amyloidosis
33 clinical trials for this condition and its sub-types, 22 tagged with Primary systemic amyloidosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug combo aims to tame rare heart disease
Disease control OngoingThis phase 2 trial tests a drug combination including daratumumab for people with AL amyloidosis, a rare disease where abnormal proteins damage organs, especially the heart. The study has two groups: one gets the full combo right away, the other starts some drugs later. Researche…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC